logo-loader
viewFSD Pharma

FSD Pharma notifies Health Canada it will forfeit licenses of subsidiary FV Pharma and suspend operations

The group has begun the process of liquidating all FV Pharma assets, including the sale of the company’s medical cannabis production facility in Cobourg, Ontario

coronavirus
CEO Dr Raza Bokhari says the company is now focused on advancing its lead compound FSD201 to treat coronavirus (COVID-19) patients

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) has notified Health Canada it will forfeit the licenses of its wholly-owned subsidiary FV Pharma Inc and suspend all activities within 30 days of the notification date.

In a statement Thursday, the company said it has begun the process of liquidating all FV Pharma assets, including the sale of the company’s medical cannabis production facility in Cobourg, Ontario.

CEO Dr Raza Bokhari said the decision to shutter the subsidiary is in the best interests of shareholders as the company now focuses on advancing its lead compound FSD201 to treat hospitalized coronavirus (COVID-19) patients and expanding its overall drug pipeline. 

READ: FSD Pharma announces US$20M offering to help fund research on lead drug candidate FSD-201

Bokhari said the company is actively working to submit an Investigational New Drug Application (IND) to the US Food and Drug Administration to use FSD201 as a way to reduce lung inflation caused by small proteins called cytokines that are central to the “cytokine storm” phenomenon, where the body starts to attack its own cells rather than just fighting off the SARS-CoV-2 virus.

“We are hopeful to initiate the Phase 2 clinical trial before the end of this year and remain cautiously optimistic that our study may improve treatment outcome for COVID-19 patients," he said.

FSD Pharma said it is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 (or the SARS-2 coronavirus) at this time.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: FSD Pharma

Price: 4.15 CAD

CSE:HUGE
Market: CSE
Market Cap: $42.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

FSD Pharma raises more than C$10M in private placement, makes progress with...

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE.CN) CEO Raza Bokhari tells Proactive how the firm is planning to use its recently-raised C$10.125 million. Bokhari says the Cobourg, Ontario-headquartered company had struck agreements with institutional investors for the purchase and sale of 1.5 million of...

on 06/12/2020

2 min read